GBIO News and Press, Generation Bio Co. From 07/08/21

CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the William B...

CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the JMP Secur...

CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the Jefferies ...

Durable, therapeutically relevant levels of anti-SARS-CoV-2 spike antibodies produced from the liver in a mouse model Next-generation rapid enzymatic synthesis of closed-ended DNA further increases the efficiency and scale of the manufacturing platform Potent factor VIII...

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced three digital presentations at the American Society of Gene & Cell Therapy (ASGCT) 2021 Vi...

The following slide deck was published by Generation Bio Co. in conjunction with this event. For further details see: Generation Bio (GBIO) Investor Presentation - Slideshow

CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a firesi...

An update on the 20 life sciences companies Numenor Capital has profiled so far range from cell therapy companies like SQZ Biotech and Orchard Therapeutics to biologics platforms like Pandion. The best performing investment, over 170% return, so far has been Pandion Therapeutics that ...

Generation Bio (GBIO): Q4 GAAP EPS of -$0.53 misses by $0.03.Cash, cash equivalents and marketable securities of $262.3MPress Release For further details see: Generation Bio EPS misses by $0.03

$262.3 million cash balance at the end of 2020 bolstered by additional net proceeds of $211.3 million from follow-on offering, funding key milestones into 2024 Ron Cooper appointed to Board of Directors Company remains on track to begin IND-enabling studies for hemophilia ...